Form 4: Plus Therapeutics Director Howard Clowes Acquires 5,000 Shares
SEC Form 4 Filing
Director Howard Clowes purchased 5,000 shares of Plus Therapeutics (PSTV) at $1.3362 per share on September 11, 2024.
Summary
- On September 11, 2024, Howard Clowes, a director of Plus Therapeutics, Inc. (PSTV), acquired 5,000 shares of common stock.
- The purchase price was $1.3362 per share.
- Following the transaction, Clowes directly owns 26,497 shares of Plus Therapeutics.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but the transaction is relatively small and may not be highly significant.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into a company's prospects, as perceived by its executives and directors.
Stakeholder Impact
- The purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/11/2024 | Date of transaction: Howard Clowes purchased 5,000 shares of Plus Therapeutics. |
| 09/13/2024 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Insider Trading, Stock Acquisition, Howard Clowes, Plus Therapeutics, PSTV, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.